23andMe
Genetic Resilience
Genetic Resilience
Tanya Lewis | Apr 11, 2016
An analysis of the genomes of nearly 600,000 healthy individuals reveals a handful of people who appear resistant to certain genetic disorders.
GWAS IDs “Morning People”
GWAS IDs “Morning People”
Catherine Offord | Feb 4, 2016
In a large genome-wide association study, researchers from 23andMe locate 15 DNA regions associated with people’s preferences for early morning starts.
Following FDA OK, 23andMe to Expand Health Prediction
Following FDA OK, 23andMe to Expand Health Prediction
Kerry Grens | Oct 21, 2015
The personal genomics firm is ramping up its suite of disease-related genetic tests.
23andMe Enters Drug Development
23andMe Enters Drug Development
Kerry Grens | Mar 12, 2015
The personal genomics firm announces plans to make medicines.
FDA OKs 23andMe Test
FDA OKs 23andMe Test
Kerry Grens | Feb 20, 2015
The US Food and Drug Administration will allow the personal genomics company to resume a disease-risk analysis.
23andMe Partners with Pfizer
23andMe Partners with Pfizer
Jef Akst | Jan 13, 2015
The personal genomics company strikes yet another deal to glean biomedically relevant information from its user data.
23andMe, Genentech Partner on Parkinson’s
23andMe, Genentech Partner on Parkinson’s
Tracy Vence | Jan 7, 2015
Firms enter a multi-year deal for the analysis of whole-genome sequence data, with an eye toward drug discovery for Parkinson’s disease.
23andMe Expands to U.K.
23andMe Expands to U.K.
Kerry Grens | Dec 2, 2014
British consumers can buy the genetic testing-associated health prediction service forbidden by the US government.
GeneLink Settles
GeneLink Settles
Abby Olena | Jan 14, 2014
Another personal genomics company faces government pressure—this time from the Federal Trade Commission.
23andMe Steps Back
23andMe Steps Back
Abby Olena | Dec 6, 2013
The company announces that it will stop offering health interpretations of personal genetic data.